Patents Represented by Attorney, Agent or Law Firm Incyte Pharmaceuticals, Inc.
  • Human cytosolic isocitrate dehydrogenase
    Patent number: 5952177
    Abstract: The invention provides a human cytosolic isocitrate dehydrogenase (HCID) and polynucleotides which identify and encode HCID. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating disorders associated with expression of HCID.
    Type: Grant
    Filed: December 3, 1997
    Date of Patent: September 14, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Preeti Lal, Neil C. Corley, Janice Au-Young
  • DNA encoding a human progesterone receptor complex p23-like protein
    Patent number: 5952175
    Abstract: The invention provides a human progesterone receptor complex p23-like protein (PR23P) and polynucleotides which identify and encode PR23P. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating and preventing disorders associated with expression of PR23P.
    Type: Grant
    Filed: October 9, 1997
    Date of Patent: September 14, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Henry Yue, Neil C. Corley, Purvi Shah
  • Human growth-related CDC10 homolog
    Patent number: 5952214
    Abstract: The invention provides a human growth-related CDC10 homolog (GR-SEP) and polynucleotides which identify and encode GR-SEP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating and preventing disorders associated with expression of GR-SEP.
    Type: Grant
    Filed: December 4, 1998
    Date of Patent: September 14, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Henry Yue, Karl J. Guegler, Matthew R. Kaser, Preete Mathur
  • Human arsenite-resistance protein
    Patent number: 5952479
    Abstract: The invention provides a human arsenite-resistance protein (NITE) and polynucleotides which identify and encode NITE. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of NITE.
    Type: Grant
    Filed: May 7, 1998
    Date of Patent: September 14, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Neil C. Corley, Chandra Patterson
  • Method of screening for ATP synthase Fo subunit
    Patent number: 5948625
    Abstract: The present invention provides a human ATP synthase d subunit (ASYSD) and polynucleotides which encode ASYSD. The invention also provides expression vectors, host cells, agonists, antisense molecules, antibodies, or antagonists. The invention also provides methods for producing ASYSD and for treating disorders associated with expression of ASYSD.
    Type: Grant
    Filed: June 9, 1998
    Date of Patent: September 7, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Surya K. Goli
  • Human zygin-1
    Patent number: 5948619
    Abstract: The invention provides a human zygin-1 (ZY-1H) and polynucleotides which identify and encode ZY-1H. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of ZY-1H.
    Type: Grant
    Filed: July 31, 1997
    Date of Patent: September 7, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Neil C. Corley, Karl J. Guegler, Purvi Shah
  • Method of detecting human phospholipase inhibitor
    Patent number: 5948626
    Abstract: The present invention provides a polynucleotide (gipl) the partial sequence for which was initially isolated from a THP-1 cDNA library and which identifies and encodes a novel human phospholipase inhibitor (GIPL). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding GIPL. The invention also provides for the use of purified GIPL and its agonists in pharmaceutical compositions for the treatment of diseases associated with the abnormal or excess phospholipase activity. Additionally, the invention provides for the use of antisense molecules to gipl or inhibitors of GIPL in pharmaceutical compositions for the prevention of pregnancy or treatment of Alzheimer's disease.
    Type: Grant
    Filed: September 15, 1998
    Date of Patent: September 7, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Phillip R. Hawkins, Lynn E. Murry
  • Polynucleotides encoding a metal response element binding protein
    Patent number: 5948641
    Abstract: The present invention provides a metal response element binding protein (MERESP) and polynucleotides which identify and encode MERESP. The invention also provides expression vectors, host cells, agonists, antibodies, and antagonists. The invention also provides methods for treating disorders associated with expression of MERESP.
    Type: Grant
    Filed: May 29, 1997
    Date of Patent: September 7, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Preeti Lal, Purvi Shah, Neil C. Corley
  • Nucleic acids encoding two human heat shock protein homologs, and methods of detection thereof
    Patent number: 5945287
    Abstract: The invention provides two human heat shock protein homologs (HSPHH-1, HSPHH-2) and polynucleotides which identify and encode HSPHH-1 and HSPHH-2. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of HSPHH-1 and HSPHH-2.
    Type: Grant
    Filed: November 19, 1997
    Date of Patent: August 31, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Purvi Shah, Neil C. Corley, Preeti Lal
  • Human longevity-assurance protein homologs
    Patent number: 5945330
    Abstract: The invention provides two human longevity-assurance protein homologs, designated individually as LAPH-1 and LAPH-2 and collectively as LAPH, and polynucleotides which identify and encode LAPH. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of LAPH.
    Type: Grant
    Filed: July 30, 1997
    Date of Patent: August 31, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Neil C. Corley, Purvi Shah, Preeti Lal
  • Human oxidized LDL receptor
    Patent number: 5945308
    Abstract: The invention provides a human oxidized LDL receptor (HOLR) and polynucleotides which identify and encode HOLR. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HOLR.
    Type: Grant
    Filed: April 3, 1998
    Date of Patent: August 31, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Y. Tom Tang, Chandra Patterson, Neil C. Corley, Susan Sather
  • Chemokine expressed in fetal spleen and its production
    Patent number: 5945506
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel expressed chemokine (FSEC) from human fetal spleen cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode FSEC, expression vectors for the production of purified FSEC, antibodies capable of binding specifically to FSEC, hybridization probes or oligonucleotides for the detection of FSEC-encoding nucleotide sequences, genetically engineered host cells for the expression of FSEC, diagnostic tests for chemokine activation based on FSEC-encoding nucleic acid molecules and antibodies capable of binding specifically to the protein.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: August 31, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Roger Coleman, Craig G. Wilde, Jeffrey J. Seilhamer
  • Ras protein
    Patent number: 5945306
    Abstract: The invention provides two human Ras proteins, referred to collectively as "RAPR" and individually as "RAPR-1" and "RAPR-2", and polynucleotides which identify and encode RAPR. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for preventing and treating disorders associated with expression of RAPR.
    Type: Grant
    Filed: December 16, 1997
    Date of Patent: August 31, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Jennifer L. Hillman, Karl J. Guegler, Y. Tom Tang, Neil C. Corley
  • Human phospholemman-like protein
    Patent number: 5945505
    Abstract: The present invention provides a novel human phospholemman-like protein (HPLP) and the polynucleotides which identify and encode HPLP. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding HPLP and for a method for producing the protein. The invention also provides pharmaceutical compositions containing HPLP and the use of such compositions for the prevention or treatment of diseases associated with the expression of HPLP. Additionally, the invention provides antisense molecules to HPLP and their use in the treatment of diseases associated with the expression of HPLP. The invention also provides diagnostic assays which utilize polynucleotides which hybridize with naturally occurring sequences encoding HPLP and antibodies which specifically bind to the protein.
    Type: Grant
    Filed: December 15, 1998
    Date of Patent: August 31, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Surya K. Goli
  • Viral receptor protein
    Patent number: 5942606
    Abstract: The invention provides a human viral receptor protein (ACVRP) and polynucleotides which identify and encode ACVRP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of ACVRP.
    Type: Grant
    Filed: November 24, 1997
    Date of Patent: August 24, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Preeti Lal, Neil C. Corley
  • Amino acid permease homolog
    Patent number: 5942399
    Abstract: The invention provides a human amino acid permease homolog (AAPH) and polynucleotides which identify and encode AAPH. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of AAPH.
    Type: Grant
    Filed: May 6, 1998
    Date of Patent: August 24, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Henry Yue, Neil C. Corley
  • Human GTP binding protein gamma-3
    Patent number: 5935812
    Abstract: The present invention provides a polynucleotide which identifies and encodes a novel human GTP binding protein gamma-3 (HGPG) and HGPG itself. The invention provides for genetically engineered expression vectors, host cells containing the vector and a method for producing HGPG. The invention also provides a method for identifying pharmaceutical compositions inhibiting the expression and activity of HGPG and for the use of such compositions for the treatment of cancer. The invention also provides diagnostic assays which utilize the polynucleotide to hybridize with the transcripts encoding HGPG or anti-HGPG antibodies which specifically bind to HGPG in normal or diseased tissues.
    Type: Grant
    Filed: September 18, 1996
    Date of Patent: August 10, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Surya K. Goli, Lynn E. Murry
  • Human pancreatitis-associated protein
    Patent number: 5935813
    Abstract: The present invention provides a novel human C-type lectin (human PAP-2) and polynucleotides which identify and encode human PAP-2. The invention also provides expression vectors, host cells, agonists, antibodies or antagonists. The invention also provides methods for treating or preventing diseases associated with expression of human PAP-2.
    Type: Grant
    Filed: March 20, 1997
    Date of Patent: August 10, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Surya K. Goli
  • Human apoptosis-related calcium-binding protein
    Patent number: 5935931
    Abstract: The present invention provides a human apoptosis-related calcium-binding protein (HARC) and polynucleotides which identify and encode HARC. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HARC and a method for producing HARC. The invention also provides for agonists, antibodies, or antagonists specifically binding HARC, and their use, in the prevention and treatment of diseases associated with expression of HARC. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HARC for the treatment of diseases associated with the expression of HARC. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HARC.
    Type: Grant
    Filed: June 9, 1998
    Date of Patent: August 10, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Surya K. Goli
  • cDNA encoding a human cystatin-like protein (CSTIN)
    Patent number: 5935817
    Abstract: The present invention provides a human cystatin-like protein (CSTIN) and polynucleotides which identify and encode CSTIN. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding CSTIN and a method for producing CSTIN. The invention also provides for agonists, antibodies, or antagonists specifically binding CSTIN, and their use, in the prevention and treatment of diseases associated with expression of CSTIN. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding CSTIN for the treatment of diseases associated with the expression of CSTIN. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding CSTIN.
    Type: Grant
    Filed: January 30, 1997
    Date of Patent: August 10, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Surya K. Goli